Corbus gets $25M from CF Foundation for Ph IIb study

The not-for-profit Cystic Fibrosis Foundation (Bethesda, Md.) awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of

Read the full 251 word article

User Sign In